Psychosis is a disruption in how someone experiences reality — it is a symptom, not a diagnosis, and it can respond remarkably well to treatment, especially when caught early. This guide explains what psychosis is, what causes it, and what actually helps.
15 min read Reviewed July 2026 Plain-language summary
The short version
Psychosis is a symptom — a break from shared reality — that appears in several conditions, not only schizophrenia.
Early intervention in first-episode psychosis (FEP) dramatically improves long-term outcomes; time to treatment matters.
Schizophrenia is a chronic condition that requires ongoing treatment, but most people can live meaningful lives with the right support.
Coordinated Specialty Care (CSC) is the evidence-based standard for early psychosis — NH has CSC programs.
Negative symptoms (withdrawal, flat affect, low motivation) are often more disabling than positive symptoms, and harder to treat.
What psychosis is
Psychosis is not a diagnosis — it is a syndrome, a disruption in the ability to distinguish what is real from what is not. The word comes from the Greek psyche (mind) and osis (abnormal condition). It can appear in many conditions: schizophrenia, bipolar disorder with psychotic features, major depression with psychotic features, substance use, medical conditions (including epilepsy, thyroid disorders, and infections), and as a side effect of some medications.
Psychosis is not the same as “crazy,” dangerous, or untreatable — all three assumptions are wrong and cause enormous harm. It is a medical phenomenon with identifiable neurobiology, effective treatments, and, in many cases, excellent prognosis when recognized and treated early.
Psychosis is more common than people think
About 3% of people will experience a psychotic episode at some point in their lives. Most will not develop schizophrenia. Brief psychotic disorder, substance-induced psychosis, and psychosis in the context of a mood disorder together account for many more cases than schizophrenia.
Positive and negative symptoms
Clinicians divide psychosis symptoms into two categories — not “good and bad” but “added to and subtracted from” normal experience:
Positive symptoms
Things added to normal experience
Hallucinations — perceiving things that others do not: voices (most common), visions, smells, tastes, or physical sensations. The voices are experienced as entirely real.
Delusions — fixed, false beliefs held with certainty despite contradicting evidence. Common types: paranoid (being followed, poisoned), referential (events or media are about them), grandiose, somatic, or bizarre.
Disorganized thinking — loose associations, tangential speech, thought blocking, or incoherence that makes communication hard to follow.
Disorganized behavior — unpredictable, purposeless actions; catatonia in severe cases.
Negative symptoms
Things subtracted from normal experience
Avolition — severely reduced motivation and goal-directed activity; not laziness but an inability to initiate.
Alogia — reduced speech output; brief, empty replies; poverty of thought content.
Anhedonia — diminished ability to feel pleasure, even from previously enjoyed activities.
Asociality — decreased desire for social interaction; withdrawal from relationships.
Negative symptoms are often the most persistent and the most disabling. They are less well understood, harder to treat with current medications, and frequently mistaken for depression, medication side effects, or personality. They account for much of the long-term functional impairment in schizophrenia.
Cognitive impairments — in attention, working memory, processing speed, and executive function — represent a third domain, sometimes called the “hidden” symptoms. These frequently predate psychosis onset and are strong predictors of functional outcome.
The schizophrenia spectrum
The DSM-5-TR groups psychotic conditions along a spectrum of severity and duration:
Brief Psychotic Disorder
Psychotic symptoms lasting 1 day to 1 month, with full return to prior functioning. Often triggered by a stressor. Prognosis is generally very good.
Schizophreniform Disorder
Symptoms lasting 1–6 months. A provisional diagnosis that may resolve or evolve into schizophrenia depending on trajectory.
Schizophrenia
Symptoms for ≥6 months, with ≥1 month of active-phase symptoms (at least two of: hallucinations, delusions, disorganized speech, disorganized behavior, negative symptoms). A chronic condition with variable course — some people achieve near-full recovery; others have persistent disability. Onset typically in late teens to mid-30s, with men averaging 5 years earlier onset than women.
Schizoaffective Disorder
A combination of schizophrenia symptoms with a major mood episode (depressive or manic) present for the majority of the illness. Often debated diagnostically — sits between schizophrenia and bipolar with psychotic features on the spectrum.
Delusional Disorder
One or more delusions for ≥1 month, without the other prominent features of schizophrenia. Functioning outside the delusional domain may be relatively preserved. Often difficult to treat.
Psychosis also occurs as a specifier in major depressive disorder and bipolar I disorder. These presentations require treatment of both the psychotic and the mood component.
Early psychosis and first-episode psychosis (FEP)
First-episode psychosis (FEP) — the first time someone experiences psychosis — is a critical window. Before this, many people pass through a prodromal phase: a period of gradual, non-specific changes in functioning (social withdrawal, declining performance, perceptual disturbances, unusual beliefs) that can precede frank psychosis by months to years.
The duration of untreated psychosis (DUP) — the time between psychosis onset and first treatment — is one of the strongest predictors of long-term outcome. Shorter DUP correlates with faster remission, better cognitive outcomes, and lower relapse rates. Every month matters.
DUP in the US averages 74 weeks
The national average time from first psychotic symptoms to first treatment is roughly 74 weeks — nearly a year and a half. This represents an enormous opportunity cost. Early psychosis programs specifically aim to compress this gap.
Coordinated Specialty Care (CSC) is the SAMHSA-endorsed and evidence-supported treatment model for first-episode psychosis. It combines:
Low-dose antipsychotic medication
Individual therapy (CBT-p is first-line)
Family psychoeducation and support
Supported employment and education (IPS model)
Case management and care coordination
Peer support
The RAISE ETP trial demonstrated that CSC produces significantly better symptoms, functioning, and quality of life compared to usual care, with greater benefits the earlier treatment begins.
What causes psychosis
No single cause explains psychosis. Current models point to a neurodevelopmental process where genetic vulnerability interacts with environmental stressors:
Genetics: Heritability of schizophrenia is estimated at ~80%. First-degree relatives have a 10% lifetime risk (vs. ~1% in the general population). No single gene — hundreds of common variants contribute small risks.
Dopamine dysregulation: The dopamine hypothesis (subcortical hyperdopaminergia producing positive symptoms; prefrontal hypodopaminergia contributing to negative symptoms) has the most pharmacological support and explains why dopamine-blocking antipsychotics reduce positive symptoms.
Glutamate and NMDA: NMDA receptor hypofunction is implicated in both positive and negative symptoms, and may explain why dopamine-only treatments leave much unaddressed.
Neurodevelopment: Prenatal and early-life factors — viral infection in pregnancy, obstetric complications, urban birth — increase risk. Brain changes predating psychosis are subtle but measurable.
Cannabis: High-potency cannabis (THC-dominant) meaningfully increases psychosis risk, particularly in genetically vulnerable individuals and with use before age 18. This is a modifiable risk factor.
Adverse childhood experiences: Trauma, abuse, and neglect substantially increase risk independent of genetics.
Treatment
Treatment for schizophrenia and related psychotic disorders is multimodal. No single intervention is sufficient.
Antipsychotic medication
Antipsychotics are the foundation of treatment for positive symptoms. Second-generation (atypical) antipsychotics are generally first-line: aripiprazole (Abilify), risperidone, quetiapine, olanzapine, lurasidone, ziprasidone, and others. Long-acting injectable (LAI) formulations — given every 2–12 weeks — dramatically improve adherence and reduce relapse risk and are underused relative to their evidence base.
Clozapine — the only antipsychotic with demonstrated superiority for treatment-resistant schizophrenia — is underused due to monitoring burden (mandatory ANC testing for agranulocytosis) but can be transformative for the approximately 30% of patients who do not respond to two or more other agents.
Psychotherapy
Cognitive Behavioral Therapy for Psychosis (CBT-p) is the most evidence-supported psychotherapy. It addresses distressing beliefs and voices, develops coping strategies, and improves insight without demanding that the person surrender their beliefs. Unlike medication, it can continue working during and after active symptoms. Acceptance and Commitment Therapy (ACT) and metacognitive training (MCT) have emerging evidence.
Cognitive remediation
Computerized and therapist-guided cognitive training targets attention, memory, and processing speed. When combined with supported employment, it produces additive functional gains.
Social skills training
Structured skills training addresses the social cognitive impairments that affect relationship functioning. Particularly helpful when negative symptoms include asociality.
Medication adherence is the most modifiable outcome predictor
Nonadherence is the single largest driver of relapse in schizophrenia, and relapses cause cumulative harm — each episode is associated with greater cognitive and functional impairment. Motivational interviewing, shared decision-making, and LAIs all improve adherence.
Recovery
Recovery from schizophrenia is not binary. Research shows a wide range of long-term outcomes, including a significant group who achieve full or near-full remission. The WHO's international studies found better outcomes in some lower-income countries, challenging the narrative that schizophrenia is inevitably and uniformly severe.
The Recovery Movement reframes the goal: not elimination of symptoms, but living a meaningful, self-directed life. Employment, housing, relationships, and community participation are outcomes that matter regardless of symptom burden.
IPS (Individual Placement and Support) is the evidence-based model for supported employment — it outperforms pre-vocational training in every domain and should be available to anyone who wants to work.
Peer support workers with lived experience of psychosis are a valued part of CSC teams and improve engagement, especially early in treatment.
Housing First approaches serve people with serious mental illness better than treatment-first conditional housing models.
For family members
When someone you love is experiencing psychosis, the experience can be terrifying and disorienting — for them and for you. A few evidence-based principles help:
Don't argue about delusions.Arguing rarely helps and can damage trust. You don't have to agree — you can say “I know you believe that, and I'm worried about you” without confirming or disputing the belief.
Low-stimulation environment helps. High expressed emotion (criticism, hostility, or emotional over-involvement) in the home is associated with higher relapse rates. Calm, structured, predictable environments support recovery.
Family psychoeducation works. Structured programs (NAMI Family-to-Family, Family Connections, NAVIGATE family education) reduce relapse and improve family wellbeing. These are free.
Mobile crisis is often better than 911. NH Rapid Response (833-710-6477) and CMHC mobile teams can respond without law enforcement — often a safer option during a mental health crisis.
Anosognosia is part of the illness. Lack of insight — genuinely not believing one is ill — affects over 50% of people with schizophrenia. It is a neurological feature of the condition, not stubbornness or denial. LEAP (Listen, Empathize, Agree, Partner) is a communication approach designed for low-insight situations.
NAMI NH offers free family support
NAMI New Hampshire runs Family-to-Family (a free 8-week course for family members), Family Support Groups, and the Peer-to-Peer program for people with lived experience. All are free and available statewide. Call 603-225-5359 or visit naminh.org.
1.American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
2.Kane, J. M., et al. (2015). Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. American Journal of Psychiatry, 173(4), 362–372.
3.McGorry, P. D., et al. (2008). Early intervention in psychosis: Concepts, evidence and future directions. World Psychiatry, 7(3), 148–156.
4.Leucht, S., et al. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063–2071.
5.Wykes, T., et al. (2011). A meta-analysis of cognitive remediation for schizophrenia: Methodology and effect sizes. American Journal of Psychiatry, 168(5), 472–485.
6.Burns, T., et al. (2007). Individual placement and support vs standard vocational rehabilitation in severe mental illness: A randomised controlled trial. The Lancet, 370(9593), 1146–1152.
7.Andreasen, N. C., et al. (2005). Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry, 162(3), 441–449.
8.SAMHSA. (2015). Behavioral health treatment services locator. Coordinated specialty care for first episode psychosis. https://www.samhsa.gov
This page is general education, not medical advice or a diagnosis. Mental health conditions are best assessed and treated by a qualified professional. If you or someone else is in immediate danger, call or text 988(Suicide & Crisis Lifeline) or NH Rapid Response at 833-710-6477.